THIS WEEK IN THE PUBLIC INDEX
This week in the index · AI biopharma and virtual life sciences
2026-10-05 — 2026-10-09 · Public source records indexed from Monday 00:00 Beijing time to page generation.
95 currently public indexed records
51 industry source records · 44 AI research records in selected journals · 14 sources with indexed records.
Window starts 2026-10-04T16:00:00.000Z; generated 2026-10-09T07:48:46.430Z (UTC). Dates above use Beijing time. Counts are computed before display limits using the public-resource deduplication rules. Revoked sources or changes to public scope are reflected in recalculated counts and lists.
| Topic | Indexed this week | Explore |
|---|---|---|
| AI virtual cells | 9 | Source records for this topic → |
| Organoids | 13 | Source records for this topic → |
| AI virtual embryos | 0 | Source records for this topic → |
| AI virtual organs | 1 | Source records for this topic → |
| AI drug discovery | 74 | Source records for this topic → |
Topics are automated discovery categories; a source record may belong to more than one topic. Zero means no matching public record in this indexing window, not that no industry progress occurred.
This week’s indexed records and sources
Showing the latest 30 records, up to 30; the complete count is 95. Each links to its record here and the original source.
Diffusing protein binders to intrinsically disordered proteins
Crossref REST API · Indexed academic record · Source published: Wed Jul 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Fri Oct 09 2026 06:07:46 GMT+0000 (Coordinated Universal Time)
Abstract Proteins that bind to intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs) with high affinity and specificity could be useful for therapeutic and diagnostic applications 1–4 . How
Computational design of metallohydrolases
Crossref REST API · Indexed academic record · Source published: Wed Dec 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 11:07:46 GMT+0000 (Coordinated Universal Time)
Abstract De novo enzyme design seeks to build proteins containing ideal active sites with catalytic residues surrounding and stabilizing the transition state(s) of the target chemical reaction 1–7 . The generative artifi
AlphaFold ‘goes viral’: database adds protein complexes of common viruses
Crossref REST API · Indexed academic record · Source published: Thu Sep 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 11:07:46 GMT+0000 (Coordinated Universal Time)
AlphaFold ‘goes viral’: database adds protein complexes of common viruses
Sampling protein language models for functional protein design
Crossref REST API · Indexed academic record · Source published: Date not provided · Indexed here: Thu Oct 08 2026 09:31:31 GMT+0000 (Coordinated Universal Time)
Sampling protein language models for functional protein design
Robust out-of-distribution prediction of Buchwald–Hartwig reactions
Crossref REST API · Indexed academic record · Source published: Mon Aug 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:29:04 GMT+0000 (Coordinated Universal Time)
Abstract The Buchwald–Hartwig cross-coupling is a cornerstone of modern pharmaceutical synthesis, yet predictive modeling of its outcomes remains constrained by data quality and chemical space coverage. Electronic labora
Multistate and functional protein design using RoseTTAFold sequence space diffusion
Crossref REST API · Indexed academic record · Source published: Wed Sep 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:21:33 GMT+0000 (Coordinated Universal Time)
Abstract Protein denoising diffusion probabilistic models are used for the de novo generation of protein backbones but are limited in their ability to guide generation of proteins with sequence-specific attributes and fu
Atomically accurate de novo design of antibodies with RFdiffusion
Crossref REST API · Indexed academic record · Source published: Wed Nov 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:15:50 GMT+0000 (Coordinated Universal Time)
Abstract Despite the central role of antibodies in modern medicine, no method currently exists to design novel, epitope-specific antibodies entirely in silico. Instead, antibody discovery currently relies on immunization
De novo designed proteins neutralize lethal snake venom toxins
Crossref REST API · Indexed academic record · Source published: Wed Jan 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:15:48 GMT+0000 (Coordinated Universal Time)
Abstract Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more 1,2 . Three-finger tox
Engineering human multi-organ tissue chip niches for drug absorption, distribution, metabolism, excretion and toxicity prediction.
PubMed / NCBI E-utilities · Indexed academic record · Source published: Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:09:29 GMT+0000 (Coordinated Universal Time)
Predicting human drug responses in vitro remains a central challenge in drug development. Animal models have shown limited accuracy in recapitulating human drug absorption, distribution, metabolism, excretion and toxicit
Owkin to Integrate Kognitic's Clinical Trial Data Into K Pro Through New Collaboration
Owkin official newsroom · Indexed industry source record · Source published: Thu Aug 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:09:24 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company pioneering Biological Artificial SuperIntelligence to revolutionize drug discovery and development, today announced a data collaboration with Kognitic to integrate Kogniti
Isomorphic Labs announces $600m external investment round
Isomorphic Labs official announcements · Indexed industry source record · Source published: Mon Mar 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:09:23 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with participation from GV, and follow-on capital fro
CytoVI: deep generative modeling of antibody-based single cell data.
PubMed / NCBI E-utilities · Indexed academic record · Source published: Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Antibody-based single-cell technologies, such as flow cytometry, mass cytometry and CITE-seq, have become widely used in clinical diagnostics and basic research; however, their analysis is complicated by technical noise,
FLIGHTED: Inferring fitness landscapes from noisy high-throughput experimental data.
PubMed / NCBI E-utilities · Indexed academic record · Source published: Fri Oct 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Machine learning (ML) for protein design requires large protein fitness datasets generated by high-throughput experiments for training and benchmarking models. However, most models do not account for experimental noise i
Function-preserving watermarking of AI-generated proteins.
PubMed / NCBI E-utilities · Indexed academic record · Source published: Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Generative artificial intelligence (AI) models are revolutionizing biology, with tools such as AlphaFold 3 and protein design models accelerating breakthroughs in protein structure prediction and the creation of new func
Owkin and CRO Aviano Sign Master Partnership Agreement to Foster Collaborative Oncology Research
Owkin official newsroom · Indexed industry source record · Source published: Fri Aug 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:09:15 GMT+0000 (Coordinated Universal Time)
PARIS & PORDENONE, Italy — Owkin, the agentic AI company pioneering the first autonomous AI scientist to revolutionize drug discovery and development, and the Centro di Riferimento Oncologico di Aviano (CRO), a leading I
Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence
Isomorphic Labs official announcements · Indexed industry source record · Source published: Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:09:05 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs appoints Dr. Ben Wolf M.D., Ph.D., as Chief Medical Officer and establishes US Presence. Dr. Wolf will be based in the company's newly established Cambridge location, where
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin official newsroom · Indexed industry source record · Source published: Wed Sep 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:56 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together
Isomorphic Labs to appoint Max Jaderberg as President
Isomorphic Labs official announcements · Indexed industry source record · Source published: Wed Nov 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:54 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces the appointment of Max Jaderberg as President of the company effective 1 January 2026, transitioning from his current role as Isomorphic Labs’ Chief AI Officer. Co
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
Owkin official newsroom · Indexed industry source record · Source published: Fri Sep 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:48 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - September 11, 2026 — Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent
Iambic Named to CNBC Disruptor 50 for Second Consecutive Year
Iambic official newsroom · Indexed industry source record · Source published: Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:47 GMT+0000 (Coordinated Universal Time)
San Diego, CA – May 19, 2026 – Iambic is a CNBC Disruptor 50 for the second year in a row, joining the ranks of repeat Disruptors OpenAI, AirBnB, and SpaceX. The Disruptor 50 is an annual list curated by CNBC to recogniz
Isomorphic Labs Enters into a Research Collaboration with Johnson & Johnson
Isomorphic Labs official announcements · Indexed industry source record · Source published: Tue Jan 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:46 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces a cross-modality, multi-target research collaboration with Johnson & Johnson. This partnership brings together Iso’s AI-first approach to drug discovery with Johns
Machine learning for functional protein design.
Europe PMC REST API · Indexed academic record · Source published: Thu Feb 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Recent breakthroughs in AI coupled with the rapid accumulation of protein sequence and structure data have radically transformed computational protein design. New methods promise to escape the constraints of natural and
A Generative Neural Network for Maximizing Fitness and Diversity of Synthetic DNA and Protein Sequences.
Europe PMC REST API · Indexed academic record · Source published: Thu Jun 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Engineering gene and protein sequences with defined functional properties is a major goal of synthetic biology. Deep neural network models, together with gradient ascent-style optimization, show promise for sequence desi
AI-enhanced adaptive virtual screening of large libraries for ligand discovery.
Europe PMC REST API · Indexed academic record · Source published: Tue Sep 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Ultralarge virtual screenings (ULVSs) evaluate billions of molecules for drug discovery but face cost, flexibility and scalability limits. We introduce AdaptiveFlow, an open-source platform that makes ULVSs more accessib
Artificial intelligence for natural product drug discovery.
Europe PMC REST API · Indexed academic record · Source published: Mon Sep 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Developments in computational omics technologies have provided new means to access the hidden diversity of natural products, unearthing new potential for drug discovery. In parallel, artificial intelligence approaches su
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca
Owkin official newsroom · Indexed industry source record · Source published: Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:37 GMT+0000 (Coordinated Universal Time)
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their t
Bayer and Iambic collaborate to advance drug discovery with AI
Iambic official newsroom · Indexed industry source record · Source published: Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:35 GMT+0000 (Coordinated Universal Time)
Bayer and Iambic collaborate to advance drug discovery with AI Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’
Isomorphic Labs announces Series B investment round
Isomorphic Labs official announcements · Indexed industry source record · Source published: Tue May 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:33 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $2.1 Billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alon
The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development.
PubMed / NCBI E-utilities · Indexed academic record · Source published: Thu Sep 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:33 GMT+0000 (Coordinated Universal Time)
Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented. We introduce the Virtual Biotech, an organization of artificial intelligence (AI) agents modeled
Binding and sensing diverse small molecules using shape-complementary pseudocycles.
Europe PMC REST API · Indexed academic record · Source published: Thu Jul 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:29 GMT+0000 (Coordinated Universal Time)
We describe an approach for designing high-affinity small molecule-binding proteins poised for downstream sensing. We use deep learning-generated pseudocycles with repeating structural units surrounding central binding p
Reviewed events dated this week
3 events, showing up to 10. Events use occurrence dates where available, otherwise announcement dates. This differs from the source-record counts based on indexing time above.
Isomorphic Labs 加入 Virtual Biology Initiative
Wed Oct 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据 Isomorphic Labs 官方公告，加入由 Biohub 召集的 Virtual Biology Initiative，参与组织将投入数据、计算与测量技术。Biohub 尚未完成本库实体归属核验，暂不绘制关系边。
晶泰公布 XGlue 分子胶平台与临床前管线进展
Tue Oct 06 2026 03:29:09 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据晶泰官方 RSS 中的公告，XGlue 工作结合计算与实验数据训练 AI 模型，对 E3 与目标蛋白组合进行优先级判断；不把公司表述转换为临床疗效证据。
Iambic 提交第二款自有 AI 发现候选药 IAM217 的 IND
Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据 Iambic 官方公告，已提交 IAM217 的 IND 申请。提交申请不等于监管批准，也不代表临床疗效已获证实。
Reader guides: from sources to conclusions
Compare models by task and follow collaborations through evidence. Each guide includes original sources and a review date.
How should we compare virtual cells, AI models, and companies?
Compare single-cell models, structure prediction, and protein design by inputs, outputs, tasks, and validation conditions. Distinguish model papers from company capabilities.
Reader guide · updated 2026-10-08
AI drug discovery collaboration timelines: from announcements to evidence
Use real official announcements to distinguish partners, upfront payments, conditional milestones, and R&D progress, and build a traceable collaboration timeline.
Reader guide · updated 2026-10-08
How to read weekly AI drug discovery updates: companies, research, and coverage gaps
Build a weekly reading routine, distinguish announcements, papers, and clinical results, and understand this site’s weekly indexing window, denominators, and source coverage.
Reader guide · updated 2026-10-08
Check source coverage and collection status → · Subscribe to RSS →